Long‐term treatment with fostamatinib in Japanese patients with primary immune thrombocytopenia: An open‐label extension study following a phase 3 placebo‐controlled, double‐blind, parallel‐group study
American Journal of Hematology · 2024
DOI: 10.1002/ajh.27176 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift American Journal of Hematology, 2024. Verfasst von Masataka Kuwana und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Allergy and Rheumatology, Nippon Medical School Graduate School of Medicine, Japan. Hauptthemen laut MEDLINE: Purpura, Thrombocytopenic, Idiopathic, Aminopyridines, Morpholines, Pyrimidines. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 6 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Kissei Pharmaceutical Co., Ltd., Kissei.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Allergy and Rheumatology, Nippon Medical School Graduate School of Medicine, Japan.
- First Department of Internal Medicine, Kansai Medical University, Hirakata, Japan.
- Division of Hematology and Oncology, Department of Internal Medicine, Iwate Medical University, Morioka, Japan.
- Department of Hematology and Rheumatology, Nihon University School of Medicine, Tokyo, Japan.
- Department of Hematology, Fujisawa City Hospital, Fujisawa, Japan.
- Department of Hematology, Hamamatsu Medical Center, Hamamatsu, Japan.
ORCID-Profile: Masataka Kuwana, Tomoki Ito, Shugo Kowata, Yoshihiro Hatta, Katsumichi Fujimaki, Toshiya Kagoo, Yoshiaki Tomiyama
Förderung
- Kissei Pharmaceutical Co., Ltd.
- Kissei
Zitieren
APA
Kuwana, M., Ito, T., Kowata, S., Hatta, Y., Fujimaki, K., Naito, K., Kurahashi, S., Kagoo, T., Tanimoto, K., Saotome, S., & Tomiyama, Y. (2024). Long‐term treatment with fostamatinib in Japanese patients with primary immune thrombocytopenia: An open‐label extension study following a phase 3 placebo‐controlled, double‐blind, parallel‐group study. American Journal of Hematology. https://doi.org/10.1002/ajh.27176
Vancouver
Kuwana M, Ito T, Kowata S, Hatta Y, Fujimaki K, Naito K, et al. Long‐term treatment with fostamatinib in Japanese patients with primary immune thrombocytopenia: An open‐label extension study following a phase 3 placebo‐controlled, double‐blind, parallel‐group study. American Journal of Hematology. 2024. doi:10.1002/ajh.27176
BibTeX
@article{Kuwana2024,
author = {Kuwana, Masataka and Ito, Tomoki and Kowata, Shugo and Hatta, Yoshihiro and Fujimaki, Katsumichi and Naito, Kensuke and Kurahashi, Shingo and Kagoo, Toshiya and Tanimoto, Kazuki and Saotome, So and Tomiyama, Yoshiaki},
title = {Long‐term treatment with fostamatinib in Japanese patients with primary immune thrombocytopenia: An open‐label extension study following a phase 3 placebo‐controlled, double‐blind, parallel‐group study},
journal = {American Journal of Hematology},
year = {2024},
doi = {10.1002/ajh.27176}
}
EUVIMED